psychedelics investing Compass Pathways to Participate in TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026
psychedelics investing Compass Pathways Launches 'Change the Tune in TRD' in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 2026
psychedelics investing Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training
psychedelics investing Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training
psychedelics investing Compass Pathways to Participate in Investor Conferences the Week of September 14th
psychedelics investing Compass Pathways' New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year
psychedelics investing Compass Pathways to Debut U.S. HCP Education Campaign and Present New HEOR Data at Psych Congress 2026
psychedelics investing Compass Pathways to Participate in 2026 Cantor Global Healthcare Conference on September 9, 2026
psychedelics investing Compass Pathways to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026
psychedelics investing Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin
psychedelics investing Compass Pathways to Announce Second Quarter and First Half 2026 Financial Results on August 5, 2026
psychedelics investing Compass Pathways Announces Publication of Post-Hoc Analysis Demonstrating Distinction of COMP360 Trial Monitoring & Support from Psychotherapy
psychedelics investing Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile
psychedelics investing A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year
